Evidence map›Paper›PMID 32343517›Full record

ArticleSexually transmitted diseases2020

Routine HIV Test Results in 6 US Clinical Laboratories Using the Recommended Laboratory HIV Testing Algorithm With Geenius HIV 1/2 Supplemental Assay.

Laura G Wesolowski, Pollyanna R Chavez, Ana María Cárdenas, Alex Katayev, Patricia Slev, Alexandra Valsamakis, Yun F Wang, Joseph D Yao, Caitlin Dougherty, Laura Gillim-Ross and 2 more

Abstract read
In one paragraph

Article in Sexually transmitted diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Estimating the Economic Consequences of Leveraging the Novel cobas HIV-1/HIV-2 Qualitative Nucleic Acid Amplification Test in Routine HIV Testing.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Laura G WesolowskiFrom the Centers for Disease Control and Prevention, Atlanta, GA.
Pollyanna R ChavezFrom the Centers for Disease Control and Prevention, Atlanta, GA.
Ana María CárdenasChildren's Hospital of Philadelphia, Philadelphia, PA.
Alex KatayevLaboratory Corporation of America Holdings, Burlington, NC.
Patricia SlevARUP Institute for Clinical and Experimental Pathology and Department of Pathology, University of Utah, Salt Lake City, UT.
Alexandra ValsamakisJohns Hopkins Hospital, Baltimore, MD.
Yun F WangGrady Health System, Emory University, Atlanta, GA.
Joseph D YaoMayo Clinic and Mayo Clinic Laboratories, Rochester, MN.
Caitlin DoughertyChildren's Hospital of Philadelphia, Philadelphia, PA.
Laura Gillim-RossLaboratory Corporation of America Holdings, Burlington, NC.
Christopher HarmonJohns Hopkins Hospital, Baltimore, MD.
Kevin P DelaneyFrom the Centers for Disease Control and Prevention, Atlanta, GA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundGeenius HIV 1/2 Supplemental Assay (Geenius; Bio-Rad Laboratories) is the only Food and Drug Administration-approved HIV-1/HIV-2 antibody differentiation test for the second step in the HIV laboratory testing algorithm. We characterized the occurrence of true HIV-1 and HIV-2 infections as well as false results in 6 US clinical laboratories using Geenius.

methodsWe examined routine HIV testing outcome data from the time the laboratories began using the algorithm with Geenius until September 30, 2017. We calculated the positive predictive value for Geenius HIV-1 and HIV-2 reactivity separately.

resultsOf 5,046,684 specimens tested, 41,791 had reactive antigen/antibody test results. Most specimens with reactive antigen/antibody results were HIV-1 antibody-positive established infections (n = 32,421), 1,865 of which also had indeterminate HIV-2 bands present. Ninety-three specimens were HIV-2 antibody positive or untypable for HIV-1/HIV-2 antibody. Acute HIV-1 infections were found in 528 specimens; 881 specimens lacked the nucleic acid test to determine the possibility of acute HIV-1 infection. False-positive antigen/antibody test results were present in 7505 specimens. Few specimens (n = 363) had false-positive antigen/antibody results with indeterminate Geenius and negative HIV-1 nucleic acid test results. The positive predictive values of Geenius reactivity were 99.4% for HIV-1 and 4.3% for HIV-2.

conclusionsRoutine testing using the laboratory testing algorithm with Geenius resulted in most specimens resolving as HIV negative or HIV-1 positive. The occurrence of indeterminate HIV-2 bands with a Geenius final assay interpretation of HIV-1 positive was more common than true HIV-2 infections. Reporting indeterminate HIV-2 results in this situation may cause confusion with interpreting HIV infection status.

Indexed as

AlgorithmsHIV-1HIV-2HIV AntibodiesHIV InfectionsHIV TestingHumansImmunoassayLaboratoriesPredictive Value of TestsSensitivity and SpecificitySerologic TestsHIV Antibodies

Identifiers

PMID32343517
PMCPMC10949926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.